BIOLARGO, INC. – What You Need to Know

Thinking about investing in BioLargo? It is an interesting company, but before you put your money to work, you should look under the hood. Here is the plain-English breakdown of the company as of April 2026.

1. What does this company actually do?

BioLargo acts as an incubator for environmental and health technologies. They operate in three main areas:

• Environmental/Water: They focus on removing PFAS "forever chemicals" using their AEC technology and controlling odors with their CupriDyne Clean products.
• Engineering Services: Their subsidiary, BLEST, provides consulting and design services to outside clients.
• Medical/Battery: They develop advanced wound care products and specialized battery materials.

2. How do they make money?

BioLargo earns revenue through product sales, licensing fees for their patented technology, and professional engineering services.

However, it is important to note that the company is still in a "growth" phase. They currently spend more on research, legal fees, and operations than they bring in through sales. They have not yet reached consistent profitability or positive cash flow.

3. The "Pooph" Litigation: A Major Hurdle

A legal battle with their former largest customer, Pooph Inc., is a defining part of the company's current situation.

• The Conflict: BioLargo claims Pooph Inc. broke their contract and misused their intellectual property. BioLargo is seeking payment for unpaid bills and royalties, while Pooph Inc. has countersued for damages.
• Why it matters: This is a significant financial risk. In 2025, BioLargo’s revenue dropped 56% after the business relationship ended. The outcome of this lawsuit is a major "wild card" that could impact the company’s financial health and future revenue.

4. What’s the latest on their cash?

BioLargo is in a tight spot financially. By the end of 2025, they reported only $51,000 in working capital. Because of this, their auditor has issued a "going concern" warning, noting there is substantial doubt about the company’s ability to stay in business without raising more money.

• The Plan: To keep the lights on, they rely on selling new shares of stock to investors. They have an agreement in place to sell up to $10 million in stock through Clearthink Capital Partners.
• The Catch: This process causes "dilution." When the company issues new shares, your percentage of ownership in the company shrinks, which can reduce your potential earnings per share. Additionally, the company may issue "preferred stock" in the future, which could take priority over your shares.

5. Key Risks to Consider

• "Cash Burn": The company loses millions annually. Without consistent, long-term revenue, they are forced to frequently raise capital from investors to survive.
• "Penny Stock" Status: Trading at roughly $0.15 per share, the stock is highly volatile. It can be difficult to buy or sell large amounts without causing significant price swings.
• Stock Options: The company has issued over 72 million stock options. If these are exercised, it will significantly dilute the value of existing shares.
• No Dividends: They have never paid a dividend and do not plan to. Any return on your investment depends entirely on the stock price rising, which is speculative.
• Cybersecurity: Like many tech-focused firms, they face risks from potential cyber-attacks, which could lead to legal trouble and damage their reputation.

Final Thought for Investors

BioLargo is a high-risk, speculative investment. The company is currently fighting a major legal battle, is low on cash, and relies on selling new stock to fund its operations. Before investing, ask yourself if you are comfortable with the possibility of significant dilution and the risk that the company may need to raise more capital just to keep operating.

Disclaimer: I am an AI, not a financial advisor. Investing in companies that aren't yet profitable is very risky. You could lose your entire investment. Please do your own research or talk to a professional before making any financial decisions.